Drug Database
CS

CSF-G

✓ Approved

Dong-A ST · CSF3R · Recombinant Proteins

What is CSF-G?

CSF-G is a recombinant proteins developed by Dong-A ST. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

CompanyDong-A ST
Drug ClassRecombinant Proteins
Molecular TargetCSF3R
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Dong-A ST

Mechanism of Action

Molecular Targets

CSF-G acts on 1 molecular target:

CSF3Rcolony stimulating factor 3 receptor (CD114, GCSFR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

CSF-G is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersNeutropenia✓ Approved

Related Research Articles

PubMedThoracic cancer2026-10-15

Efficacy and Safety of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Patients With Solid Tumors: A Systematic Review and Meta-Analysis.

Tian Wei W, Liu Qianxin Q, Zhou Ying Y, Zhang Zhuo Z

Trilaciclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor administered before chemotherapy, reduces chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), but its efficacy across solid tumors remains unclear. This meta-analysis evaluated the efficacy and safety of trilaciclib in solid tumor patients receiving chemotherapy. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched from inception to January 21, 2026. Randomized controlled trials (RCTs) and cohort studies comparing chemotherapy with or without trilaciclib were included. Primary outcomes were severe neutropenia (SN), febrile neutropenia (FN), duration of severe neutropenia (DSN), Grade 3/4 leukopenia, and granulocyte colony-stimulating factor (G-CSF) use. Secondary outcomes included other hematologic toxicities, supportive care interventions, and efficacy outcomes. Ten studies involving 1172 patients (six RCTs and four cohort studies) were identified. Trilaciclib significantly reduced SN (OR, 0.14; 95% CI, 0.06-0.31; p < 0.001), FN (OR, 0.19; 95% CI, 0.11-0.36; p < 0.001), Grade 3/4 leukopenia (OR, 0.25; 95% CI, 0.13-0.46; p < 0.001), and G-CSF use (OR, 0.36; 95% CI, 0.18-0.71; p = 0.0087), and shortened DSN (MD, -2.30 days; 95% CI, -4.28 to -0.31; p = 0.0309). It also reduced Grade 3/4 anemia and thrombocytopenia and decreased use of erythropoiesis-stimulating agents, red blood cell transfusions, and platelet transfusions. Overall survival showed a borderline improvement (HR, 0.84; 95% CI, 0.71-0.99; p = 0.0373), while no significant differences were observed in progression-free survival, overall response rate, or non-hematologic adverse events. Subgroup analyses suggested greater benefit in ES-SCLC. Overall, trilaciclib before chemotherapy significantly reduced CIM and supportive care needs, with no apparent compromise in antitumor efficacy and more pronounced effects in ES-SCLC.

PMID 42876373
Read full article →
PubMedMovement disorders : official journal of the Movement Disorder Society2026-10-15

Neurofilament Light Chain and Mutant Huntingtin Across Huntington's Disease Integrated Staging System Stages in Huntington Disease: A Cross-Sectional Multimodal Analysis.

Pérez-Pérez Jesús J, Olmedo-Saura Gonzalo G, Puig Davi Arnau A, Pérez González Rocío R et al.

The Huntington's Disease Integrated Staging System (HD-ISS) provides a framework for staging HD but does not incorporate fluid biomarkers. The aim of this study was to examine neurofilament light chain (NfL) and mutant huntingtin (mHTT) and total tau across HD-ISS stages and their associations with genetic burden, neuroimaging, and clinical measures. We performed cross-sectional analysis of the Barcelona-Huntington's Disease (BCN-HD) cohort with external replication in the multicenter HDClarity study. HD gene expansion carriers were classified as HD-ISS stages 0 to 3. NfL (cerebrospinal fluid [CSF] and plasma), CSF mHTT, total tau, striatal volumes, and Unified Huntington's Disease Rating Scale measures were quantified. Group differences and associations were analyzed using adjusted models. The BCN-HD cohort included 78 participants (50 HD gene expansion carriers [HDGECs], 28 controls) and HDClarity included 218 participants (166 HDGECs, 52 controls). CSF NfL increased across HD-ISS stages and discriminated premanifest from manifest individuals, as well as HD-ISS stage 0 from stage 1. Plasma NfL showed parallel increases and strongly correlated with CSF NfL (ρ = 0.88, P < 0.001). More than half of HD-ISS 0 individuals had NfL levels above the age-adjusted 95th percentile (P95) and shorter predicted time to onset (13 years for CSF and 10 years for plasma). From HD-ISS 1 onward, NfL levels exceeded P95 in most individuals. Higher NfL concentrations were associated with genetic burden, striatal atrophy, and clinical measures (all P < 0.001). CSF mHTT was detectable from HD-ISS 0 but showed weaker associations, whereas CSF total tau increased only from HD-ISS 3. NfL identifies biological activity across the HD-ISS continuum and shows neuroaxonal injury in a subset of individuals classified as stage 0. These findings suggest that fluid biomarkers may complement current HD-ISS criteria and support biological stratification in observational studies and clinical trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

PMID 42876089
Read full article →
PubMedFrontiers in medicine2026-10-15

Pneumococcal meningitis secondary to chronic orbital inflammation with skull base erosion: a case report.

Tie Xinghua X, Sun Xiaoman X

This case report describes a 32-year-old female patient who developed acute pneumococcal meningitis following six-year chronic orbital inflammatory changes after strabismus corrective surgery. The patient experienced gradual deterioration of right-eye vision and recurrent retro-orbital headache; serial magnetic resonance imaging (MRI) from 2021 to 2023 demonstrated diffuse intraconal retrobulbar abnormalities and extraocular-muscle thickening. She subsequently presented with high fever, generalized seizures and impaired consciousness. Cerebrospinal fluid (CSF) metagenomic next-generation sequencing (mNGS) detected Streptococcus pneumoniae and low-abundance Epstein-Barr virus (EBV) DNA; Active EBV-associated central nervous system infection could not be confirmed in the absence of CSF quantitative EBV polymerase chain reaction (PCR), EBV serology and immune-status testing. The patient received broad-spectrum intravenous antimicrobial, antiviral and glucocorticoid therapy, followed by endoscopic endonasal resection of inflammatory lesions at the ethmoid-skull-base complex. Histopathological examination of surgical specimens revealed non-specific inflammatory granulation tissue, and Langerhans cell histiocytosis was excluded. At six-month follow-up, the patient remained seizure-free; infectious foci showed near-complete resolution on imaging, yet mild residual orbital-leptomeningeal abnormalities persisted with modest visual improvement. This case demonstrates the potential for delayed intracranial extension from long-standing chronic orbital inflammation and highlights both the diagnostic utility and interpretive limitations of CSF-mNGS in clinical practice.

PMID 42876743
Read full article →
PubMedFuture microbiology2026-10-15

Spinal neurocysticercosis: synthesizing evidence on clinical presentations, anatomical patterns, diagnostic approaches, and therapeutic strategies.

Garg Ravindra Kumar RK

Spinal neurocysticercosis (NCC) is an uncommon manifestation of NCC involving the spinal cord, meninges, nerve roots, and subarachnoid spaces. Although less common than intracranial disease, spinal involvement can cause substantial neurological morbidity because even small lesions within the confined spinal canal may produce progressive myelopathy. Disease may result from hematogenous dissemination or cerebrospinal fluid (CSF) spread of Taenia solium larvae and may present as intramedullary, intradural extramedullary, subarachnoid, or, rarely, extradural lesions. Clinical manifestations are diverse and include paraparesis, quadriparesis, cauda equina syndrome, and chronic meningitis. Magnetic resonance imaging is the diagnostic modality of choice, providing detailed assessment of lesion location, evolutionary stage, inflammatory activity, and associated complications. CSF analysis and immunological or molecular tests provide supportive evidence, while histopathological examination confirms the diagnosis when tissue is available. Treatment is individualized and may include antiparasitic agents, corticosteroids, and surgery when indicated. Although outcomes are generally favorable with early diagnosis and appropriate treatment, delayed treatment, extensive arachnoiditis, diffuse leptomeningeal disease, and established spinal cord damage may result in permanent neurological deficits. Further prospective studies are needed to refine diagnostic strategies and optimize management. PubMed database was searched from inception to 13 July 2026, for spinal neurocysticercosis and spinal cysticercosis.

PMID 42876367
Read full article →
PubMedFrontiers in oncology2026-10-15

Real-world management of ovarian cancer in women living with HIV: treatment exposure, immune monitoring, and care barriers in a five-case series.

Zhang Yang Y, Wang Fuxiang F, Guo Mingchuan M, Wan Jianyu J et al.

With improved survival among people living with HIV (PLWH), non-AIDS-defining cancers have become increasingly prominent. Women living with HIV (WLWH) remain underrepresented in ovarian cancer trials, leaving limited evidence on the tolerability of standard therapies, including chemotherapy, anti-VEGF agents, and PARP inhibitors. These patients also face unique care barriers beyond biological uncertainties. This retrospective review included five WLWH diagnosed with ovarian cancer (June 2022-March 2024). Three received anticancer treatment; one refused chemotherapy and was lost to follow-up; one had biopsy only. We collected data on demographics, HIV history, tumor characteristics, treatment exposure, adverse events (CTCAE v5.0), CD4+/CD8+ counts, and HIV RNA, focusing safety and immune analyses on the three treated patients. Median age was 51 years; four had stage III-IV disease. No treatment-related deaths, persistent HIV rebound, or AIDS-defining events occurred. During first-line paclitaxel/carboplatin, one patient developed grade 3 neutropenia managed with G-CSF, but later developed significant thrombocytopenia on niraparib requiring dose reduction and hospitalization. Among two patients receiving bevacizumab, CD4+ patterns diverged: one showed a transient decline (387 to 259 cells/μL) with concurrent nedaplatin; another maintained stable counts (150 to 200 cells/μL). One patient had transient, self-limited HIV RNA elevation concurrent with disease progression, which resolved spontaneously. This series provides real-world observations that platinum-based and targeted therapies may be delivered to selected WLWH with close monitoring. The heterogeneous CD4+ responses highlight the need for individualized immune surveillance rather than attributing changes to any single agent. Integrated oncologic-HIV care and attention to socioeconomic barriers remain critical for this underrepresented population.

PMID 42876492
Read full article →
PubMedNature communications2026-10-15

Preclinical and clinical investigation of VES001, an oral small molecule sortilin receptor inhibitor for the treatment of frontotemporal dementia: a first-in-human randomized placebo-controlled phase 1 trial.

Klem Louise L, Dumas Daniel D, Swift Imogen J IJ, Frandsen Sofie L SL et al.

GRN haploinsufficiency reduces progranulin and causes frontotemporal dementia (FTD-GRN). VES001, an oral small-molecule sortilin inhibitor, increases progranulin without downregulating sortilin. Preclinically, VES001 bound sortilin selectively and elevated progranulin in plasma, cerebrospinal fluid (CSF), and hippocampal interstitial fluid of male rats. In a randomized, double-blind, placebo-controlled first-in-human phase 1 A study, 79 healthy adults (63/37% male/female; mean age 28 years) received VES001 or placebo as single ascending doses (10-990 mg) or multiple ascending doses for 7 days (180 mg once or twice daily, or 450 mg twice daily). Safety and tolerability, the primary endpoints, were met: no deaths, serious adverse events or treatment-related discontinuations; headache and fatigue were mild and not dose-related. Pharmacokinetics were dose-proportional, with blood-brain barrier penetration. Prespecified pharmacodynamic endpoints were met as single dosing increased plasma progranulin, and twice-daily dosing produced greater, sustained increases versus placebo in plasma (peak 49% change from baseline) and CSF (18% change from baseline). Although cohorts were small, dosing lasted 7 days, and participants were healthy, these findings establish pharmacological proof of mechanism for oral sortilin inhibition and support further development of VES001 as a potential disease-modifying therapy for FTD-GRN. EU CTR 2023-505847-38-00; ClinicalTrials.gov NCT06226064.

PMID 42875454
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about CSF-G